A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.

Trial Summary

Age Range
≥30 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
LY3303560
Could I receive a Placebo?
Yes
Enrollment Goal
72
Trial Dates
Apr 25, 2016 - Jul 10, 2018
How long will I be in the trial?
Your participation could last up to 16 weeks and include 11 visits to the study center, including a 4 day clinical research unit (CRU) stay.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.